CompletedPhase 4

Pregabalin for Opiate Withdrawal Syndrome

Russia100 participantsStarted 2014-01

Plain-language summary

It is a single blind randomized symptom triggered study to assess efficacy and safety of pregablin combined with the symptom triggered treatment for opiate withdrawal syndrome vs. clonidne with the same with the symptom triggered treatment for opiate withdrawal syndrome.

Who can participate

Age range20 Years – 60 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Opioid Use Disorders; Opioid Withdrawal Syndrome Exclusion Criteria: * Severe psychiatric and somatic disorders, other Substance Use Disorders (except tobacco)

What they're measuring

Number of patients completed detoxification

Timeframe: 7 days

Trial details

NCT IDNCT03017430

SponsorSt. Petersburg Bekhterev Research Psychoneurological Institute

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2019-12

View on ClinicalTrials.gov More Opioid Withdrawal trials